Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2014

01-12-2014 | Review

Tachykinin Peptide, Substance P, and Its Receptor NK-1R Play an Important Role in Alimentary Tract Mucosal Inflammation During Cytotoxic Therapy

Authors: P. S. Satheeshkumar, Minu P. Mohan

Published in: Digestive Diseases and Sciences | Issue 12/2014

Login to get access

Abstract

The alimentary tract mucosal inflammation has been a topic of concern in oncology; though many modalities of treatment have been proposed for mucosal inflammation, the contributing adverse effects have severely affected the quality of life of patients. This review focuses on the importance of neurogenic peptide, Substance P and its receptor NK-1R in modulating the cascades of events in mucosal inflammation during cytotoxic therapy. There are various preclinical and clinical models showing increased expression of Substance P/NK-1R in ionizing radiation and chemotherapy, but only very few preclinical studies to our knowledge have highlighted or examined its role in mucosal inflammation. Hence, the importance of neuropeptide involved in the inflammatory events in mucosal inflammation in cytotoxic therapy could be a major breakthrough for future research purposes and treatment. The factors contributing to the severity of tissue reactions have been multietiogenic; thus, resultant treatment also has to be directed toward multiple contributing factors. This review also focuses on the significance of care strategy to be adopted in alimentary tract mucositis when multietiogenic factors are taken into consideration.
Literature
1.
Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110–1120.PubMedCrossRef
2.
Kim JW, Cha Y, Kim SJ, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20:395–403.PubMedCrossRef
3.
Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Cancer. 2008;113:2704–2713.CrossRef
4.
Sonis ST. Oral mucositis in head and neck cancer. Am Soc Clin Oncol Educ Book. 2013;2013:236–240.CrossRef
5.
Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21–32.PubMed
6.
Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163–171.PubMedCrossRef
7.
Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:1188–1198.PubMedCrossRef
8.
Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21:2075–2083.PubMedCrossRef
9.
Matsumoto K, Nakajima T, Sakai H, et al. Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. Dig Dis Sci. 2013;58:3440–3451.PubMedCrossRef
10.
Höckerfelt U, Franzén L, Kjörell U, Forsgren S. Parallel increase in substance P and VIP in rat duodenum in response to irradiation. Peptides. 2000;21:271–281.PubMedCrossRef
11.
Höckerfelt U, Franzén L, Forsgren S. Substance P (NK1) receptor in relation to substance P innervation in rat duodenum after irradiation. Regul Pept. 2001;98:115–126.PubMedCrossRef
12.
Forsgren S, Höckerfelt U, Norrgård O, Henriksson R, Franzén L. Pronounced substance P innervation in irradiation-induced enteropathy—a study on human colon. Regul Pept. 2000;88:1–13.PubMedCrossRef
13.
Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–4119.PubMedCrossRef
14.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.PubMedCrossRef
15.
Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.PubMedCrossRef
16.
Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci. 2006;1088:23–40.PubMedCrossRef
17.
Gerard NP, Garraway LA, Eddy RL Jr, et al. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry. 1991;30:10640–10646.PubMedCrossRef
18.
19.
Datar P, Srivastava S, Coutinho E, Govil G. Substance P: structure, function, and therapeutics. Curr Top Med Chem. 2004;4:75–103.PubMedCrossRef
20.
O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–180.PubMedCrossRef
21.
González Moles MA, Esteban F, Ruiz-Avila I, et al. A role for the substance P/NK-1 receptor complex in cell proliferation and apoptosis in oral lichen planus. Oral Dis. 2009;15:162–169.
22.
Evangelista S. Involvement of tachykinins in intestinal inflammation. Curr Pharm Des. 2001;7:19–30.PubMedCrossRef
23.
Carter MS, Krause JE. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. J Neurosci. 1990;10:2203–2214.PubMed
24.
Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol. 2000;1:392–397.PubMedCrossRef
25.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C. Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior. Physiol Behav. 1993;54:249–258.PubMedCrossRef
26.
Duffy RA, Hedrick JA, Randolph G, et al. Centrally administered Hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology. 2003;45:242–250.PubMedCrossRef
27.
Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–43.PubMedCrossRef
28.
Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.PubMedCrossRef
29.
Sonis ST. The biologic role for nuclear factor-kappa B in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389.PubMedCrossRef
30.
Logan RM, Gibson RJ, Sonis ST, Keefe DMK. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43:395–401.PubMedCrossRef
31.
32.
Kozakiewicz M, Godlewski A. Modulation of the mitotic activity and population of the mast cells in the oral mucosa by substance P. Cell Mol Biol Lett. 2003;8:727–734.PubMed
33.
Aalto Y, Forsgren S, Kjörell U, Franze´n L, Gustafsson H, Henriksson R. Time- and dose-related changes in the expression of substance P in salivary glands in response to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1995;33:297–305.
34.
Forsgren S, Franzén L, Funegård U, Gustafsson H, Henriksson R. Bilateral irradiation of head and neck induces an enhanced expression of substance P in the parasympathetic innervation of the submandibular gland. Neuroscience 1992;46:233–240.
35.
Lidegran M, Domeij S, Dalqvist Å, et al. Irradiation influences the expression of substance P and enkephalin in the rat larynx. Cell Tissue Res. 1995;279:55–63.PubMedCrossRef
36.
Alfieri AB, Cubeddu LX. Efectos de los antagonistas de los receptors NK1 y de la dexametasona sobre la inflamación neurogénica inducida porciclofosfamida y por radiación X, en la rata. AVFT. 2004;23:61–66.
37.
Goode T, O’Connell J, Sternini C, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. J Immunol. 1998;161:2232–2240.PubMed
38.
Pothoulakis C, Castagliuolo I, Leeman SE, et al. Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. Am J Physiol. 1998;275:G68–G75.PubMed
39.
Andrews PLR, Rudd JA. The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Hofmann FB, ed. Handbook of experimental pharmacology. Berlin: Springer; 2004:359–440.
40.
González Moles MA, Mosqueda-Taylor A, Esteban F et al. Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol. 2008; 44:1127–1133.
41.
Kabashima H, Nagata K, Maeda K, Iijima T. Involvement of substance P, mast cells, TNF-alpha and ICAM-1 in the infiltration of inflammatory cells in human periapical granulomas. J Oral Pathol Med. 2002;31:175–180.PubMedCrossRef
42.
Cocchiara R, Albeggiani G, Azzolina A, et al. Effect of Substance P on uterine mast cell cytokine release during the reproductive cycle. J Neuroimmunol. 1995;60:107–115.PubMedCrossRef
43.
Cocchiara R, Bongiovanni A, Albeggiani G, et al. Inhibitory effect of neuraminidase on SP-induced histamine release and TNF-α mRNA: evidence of a receptor-independent mechanism. J Neuroimmunol. 1997;75:9–18.PubMedCrossRef
44.
Kaltschmidt B, Baeuerle PA, Kaltschmidt C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol Aspects Med. 1993;14:171–190.PubMedCrossRef
45.
Azzolina A, Bongiovanni A, Lampiasi N. Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta Mol Cell Res. 2003;1643:75–83.CrossRef
46.
Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D. Substance P selectively activates TNF-alpha mRNA in rat uterine immune cells: a neuroimmune link. NeuroReport. 1997;8:2961–2964.PubMedCrossRef
47.
Azzolina A, Guarneri P, Lampiasi N. Involvement of p38 and JNK MAPKs pathways in substance P-induced production of the TNF-α by peritoneal mast cells. Cytokine. 2002;18:72–80.PubMedCrossRef
48.
Ishizuka T, Terada N, Gerwins P, et al. Mast cells tumor necrosis factor alpha production is regulated by MEK kinases. Proc Natl Acad Sci. 1997;94:6358–6363.PubMedCentralPubMedCrossRef
49.
Lorenz D, Wiesner B, Zipper J, et al. Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies. J Gen Physiol. 1998;112:577–591.PubMedCentralPubMedCrossRef
50.
Ferry X, Eichwald V, Daeffler L, Landry Y. Activation of betagamma subunits of Gi2 and Gi3 proteins by basic secretagogues induces exocytosis through phospholipases cβ and arachidonate release through phospholipase Cgamma in mast cells. J Immunol. 2001;167:4805–4813.PubMedCrossRef
51.
Page S, Fischer C, Baumgartner B, et al. 4-Hydroxynonenal prevents NFκB activation and tumor necrosis factor expression by inhibiting IκB phosphorylation and subsequent proteolysis. J Biol Chem. 1999;274:11611–11618.PubMedCrossRef
52.
Pelletier C, Varin-Blank N, Rivera J, et al. FcεRI-mediated induction of TNF-α gene expression in the RBL-2H3 mast cell line: regulation by a novel NFκB-like nuclear binding complex. J Immunol. 1998;161:4768–4776.PubMed
53.
Al-Dasooqi N, Gibson RJ, Bowen JM, Logan RM, Stringer AM, Keefe DM. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood). 2010;235:1244–1256.CrossRef
54.
Cury PR, Canavez F, de Araújo VC, Furuse C, de Araújo NS. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res. 2008;43:255–260.PubMedCrossRef
55.
Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem. 1999;274:30858–30863.PubMedCrossRef
56.
Zampetaki A, Mitsialis SA, Pfeilschifter J, Kourembanas S. Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/p44 and PI3 kinase pathways. FASEB J. 2004;18:1090–1092.PubMed
57.
58.
Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426–4441.PubMedCentralPubMedCrossRef
59.
Kefaloyianni E, Gaitanaki C, Beis I. ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell Signal. 2006;18:2238–2251.PubMedCrossRef
60.
Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–869.PubMed
61.
Alarcon-Vargas D, Ronai Z. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem. 2004;279:5008–5016.PubMedCrossRef
62.
Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell. 2004;15:713–725.PubMedCrossRef
63.
Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100–3112.PubMedCrossRef
64.
Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92:689–737.PubMedCrossRef
65.
66.
Sun J, Ramnath RD, Zhi L, Tamizhselvi R, Bhatia M. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol. 2008;294:C1586–C1596.PubMedCrossRef
67.
Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999;45:833–839.PubMedCrossRef
68.
Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;30:S41–S47.PubMedCrossRef
69.
Peters EM, Liotiri S, Bodo E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007;171:1872–1886.PubMedCentralPubMedCrossRef
70.
Chancellor-Freeland C, Zhu GF, Kage R, Beller DI, Leeman SE, Black PH. Substance P and stress-induced changes in macrophages. Ann N Y Acad Sci. 1995;771:472–484.PubMedCrossRef
71.
Paus R, Heinzelmann T, Schultz KD, Furkert J, Fechner K, Czar-netzki BM. Hair growth induction by substance P. Lab Invest. 1994;71:134–140.PubMed
72.
Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R. Hair-cycle-associated remodelling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. J Invest Dermatol. 2001;116:236–245.PubMedCrossRef
73.
Peters EM, Kuhlmei A, Tobin DJ, Muller-Rover S, Klapp BF, Arck PC. Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun. 2005;19:252–262.PubMedCrossRef
74.
Rice FL, Fundin B T, Arvidsson J, Aldskogius H, Johansson O. Comprehensive immunofluorescence and lectin binding analysis of vibrissal follicle sinus complex innervation in the mystacial pad of the rat. J Comp Neurol. 1997: 385:149–184.
75.
Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803–814.PubMedCentralPubMedCrossRef
76.
Raithel M, Schneider HT, Hahn EG. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol. 1999;34:496–503.PubMedCrossRef
77.
Mantyh PW, Catton M, Maggio JE, Vigna SR. Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. Adv Exp Med Biol. 1991;298:253–283.PubMedCrossRef
78.
Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol. 1992;87:176–181.PubMed
79.
Newson B, Dahlstrom A, Enerbäck L, Ahlman H. Suggestive evidence for a direct innervation of mucosal mast cells. Neuroscience. 1983;10:565–570.PubMedCrossRef
80.
81.
Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol. 2007;13:3027–3030.PubMedCentralPubMed
82.
Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef
83.
He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004;10:309–318.PubMed
84.
Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463:235–272.PubMedCrossRef
85.
Schemann M. Control of gastrointestinal motility by the “gut brain”—the enteric nervous system. J Pediatr Gastroenterol Nutr. 2005;41:S4–S6.PubMedCrossRef
86.
Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 1995;345:99–103.PubMedCrossRef
87.
88.
89.
90.
Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy. 2001;56:928–936.PubMedCrossRef
91.
Ray A, Sehgal PB. Cytokines and their receptors: molecular mechanism of interleukin-6 gene repression by glucocorticoids. J Am Soc Nephrol. 1992;2:S214–S221.PubMed
92.
Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF- alpha release by macrophages. Inflamm Res. 2001;50:337–340.PubMedCrossRef
93.
Franchimont D, Kino T, Galon J, Meduri GU, Chorousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 2002–2003;10:247–260.
94.
Yamaguchi M, Takizawa T, Nakajima R, Imamura R, Kasai. The Damon System and release of substance P in gingival crevicular fluid during orthodontic tooth movement in adults. World J Orthod.. 2009;10:141–146.PubMed
95.
Caviedes-Bucheli J, Azuero-Holguin MM, Gutierrez-Sanchez L, et al. The effect of three different rotary instrumentation systems on substance P and calcitonin gene-related peptide expression in human periodontal ligament. J Endod. 2010;36:1938–1942.PubMedCrossRef
96.
Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs. 2005;19:275–293.PubMedCrossRef
97.
Pike JL, Smith TL, Hauger RL, et al. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med. 1997;59:447–457.PubMedCrossRef
98.
Liu L, Markus I, Saghire HE, Perera DS, King DW, Burcher E. Gene expression in ulcerative colitis, Crohn’s disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil. 2011;23:475–483 (e179–1e80).
99.
Morse HR, Olomolaiye OO, Wood NA, Keen LJ, Bidwell JL. Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine. 1999;11:789–795.PubMedCrossRef
100.
Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis—where and how to look for it? Radiother Oncol. 2002;64:131–140.PubMedCrossRef
101.
102.
Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood).. 2009;234:430–441.PubMedCrossRef
103.
104.
Graham GJ, Stevens JM, Page NM, et al. Tachykinins regulate the function of platelets. Blood. 2004;104:1058–1065.PubMedCrossRef
105.
Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 2006;25:137–145.PubMedCrossRef
106.
Esteban F, Gonzalez-Moles MA, Castro D, et al. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology. 2009;54:258–260.PubMedCrossRef
Metadata
Title
Tachykinin Peptide, Substance P, and Its Receptor NK-1R Play an Important Role in Alimentary Tract Mucosal Inflammation During Cytotoxic Therapy
Authors
P. S. Satheeshkumar
Minu P. Mohan
Publication date
01-12-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3263-7

Other articles of this Issue 12/2014

Digestive Diseases and Sciences 12/2014 Go to the issue

Editorial

Effectiveness Research in the Evolving HCV Landscape

UNM Clinical Case Conferences

Pericardial Effusion of Obscure Origin

Original Article

Endoscopic Papillary Large Balloon Dilation for Treatment of Large Bile Duct Stones Does Not Increase the Risk of Post-procedure Pancreatitis

Correspondence

From Low-Residue Diets to Plant-Based Diets in Inflammatory Bowel Disease

Original Article

Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA

Review

Cholecystectomy for Biliary Dyskinesia: How Did We Get There?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits